Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung

被引:22
作者
Imanishi, Naoko [1 ]
Hirai, Ayako [1 ]
Yoneda, Kazue [1 ]
Shimajiri, Shohei [2 ]
Kuwata, Taiji [1 ]
Tashima, Yuko [1 ]
Takeuchi, Masahiro [3 ]
Iwai, Yoshiko [3 ,4 ]
Ichiki, Yoshinobu [1 ]
Tanaka, Fumihiro [1 ]
机构
[1] Univ Occupat & Environm Hlth, Dept Surg Chest Surg 2, Kitakyushu, Fukuoka, Japan
[2] Univ Occupat & Environm Hlth, Dept Pathol 2, Kitakyushu, Fukuoka, Japan
[3] Univ Occupat & Environm Hlth, Dept Mol Biol, Kitakyushu, Fukuoka, Japan
[4] Nippon Med Sch, Inst Adv Med Sci, Dept Biochem & Cell Biol, Tokyo, Kanagawa, Japan
基金
日本学术振兴会;
关键词
PD-L1; prognosis; pulmonary pleomorphic carcinoma; SHOW HIGH-LEVELS; SARCOMATOID CARCINOMA; CELL INFILTRATION; CANCER; ADENOCARCINOMA; DOCETAXEL; PEMBROLIZUMAB; CHEMOTHERAPY; NIVOLUMAB; THERAPY;
D O I
10.1002/jso.25041
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and ObjectivesPulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death-ligand 1 (PD-L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear. MethodsTwenty-six patients with surgically resected PPC were retrospectively reviewed. Immuno-histochemical staining was used to detect PD-L1 expression, and PD-L1 status was classified into high or low according to the percentage of tumor cells (TCs) expressing PD-L1 (tumor proportion score, TPS). ResultsPD-L1 expression was positive in 20 (76.9%) patients at the cut-off TPS value of 1%. A receiver-operating characteristic (ROC) analysis showed that the optimal cut-off value was 15% for prediction of cancer-specific death with the area under ROC curve of 0.701 (P=0.107). High PD-L1 expression was associated with a favorable overall survival (100% vs 45.9% at 5 years; P=0.046) as well as a favorable cancer-specific survival (88.9% vs 37.5% at 5 years; P=0.012). A multivariate analysis indicated a trend toward a favorable prognosis associated with high PD-L1 expression (hazard ratio [HR], 0.254 [95% confidence interval, 0.054-1.200]; P=0.084). ConclusionsPD-L1 expression was positive in most PPC cases, and high PD-L1 expression may predict a favorable prognosis in resected PPC.
引用
收藏
页码:1563 / 1569
页数:7
相关论文
共 32 条
[1]  
[Anonymous], 2016, NAT REV CANCER, DOI [DOI 10.1038/NRC3239, DOI 10.1038/NRC3239.THE]
[2]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[3]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[4]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[5]   High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma [J].
Chang, Yih-Leong ;
Yang, Ching-Yao ;
Lin, Mong-Wei ;
Wu, Chen-Tu ;
Yang, Pan-Chyr .
EUROPEAN JOURNAL OF CANCER, 2016, 60 :125-135
[6]   Oncology Meets Immunology: The Cancer-Immunity Cycle [J].
Chen, Daniel S. ;
Mellman, Ira .
IMMUNITY, 2013, 39 (01) :1-10
[7]   Clinicopathological characteristics of surgically resected pulmonary pleomorphic carcinoma [J].
Chen, Fengshi ;
Sonobe, Makoto ;
Sato, Toshihiko ;
Sakai, Hiroaki ;
Huang, Cheng-Long ;
Bando, Toru ;
Date, Hiroshi .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2012, 41 (05) :1037-1042
[8]   Molecular mechanisms of T cell co-stimulation and co-inhibition [J].
Chen, Lieping ;
Flies, Dallas B. .
NATURE REVIEWS IMMUNOLOGY, 2013, 13 (04) :227-242
[9]   Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].
Herbst, Roy S. ;
Baas, Paul ;
Kim, Dong-Wan ;
Felip, Enriqueta ;
Perez-Gracia, Jose L. ;
Han, Ji-Youn ;
Molina, Julian ;
Kim, Joo-Hang ;
Arvis, Catherine Dubos ;
Ahn, Myung-Ju ;
Majem, Margarita ;
Fidler, Mary J. ;
de Castro, Gilberto, Jr. ;
Garrido, Marcelo ;
Lubiniecki, Gregory M. ;
Shentu, Yue ;
Im, Ellie ;
Dolled-Filhart, Marisa ;
Garon, Edward B. .
LANCET, 2016, 387 (10027) :1540-1550
[10]   Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung [J].
Hirai, Ayako ;
Yoneda, Kazue ;
Shimajiri, Shohei ;
Kuroda, Koji ;
Hanagiri, Takeshi ;
Fujino, Yoshihisa ;
Tanaka, Fumihiro .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (01) :382-+